JAGUAR HEALTH, INC. Retained Earnings
JAGUAR HEALTH, INC. (JAGX) had Retained Earnings of -$403.75 million as of 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-19
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$403.75M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$391.07M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$399.92M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$376.86M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$403.75M 10-Q · filed 2026-08-19 | |
| 2026-03-31 | -$391.07M 10-Q · filed 2026-05-20 | |
| 2025-12-31 | -$399.92M 10-Q · filed 2026-08-19 | |
| 2025-09-30 | -$376.86M 10-Q · filed 2025-11-14 | |
| 2025-06-30 | -$367.35M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | -$356.95M 10-Q · filed 2025-05-15 | |
| 2024-12-31 | -$346.48M 10-K · filed 2026-04-07 | |
| 2024-09-30 | -$336.56M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | -$326.71M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | -$317.21M 10-Q · filed 2024-05-14 | |
| 2023-12-31 | -$308.25M 10-K · filed 2025-03-31 | -$308.25M 10-K · filed 2024-04-01 |
| 2023-09-30 | -$299.08M 10-Q · filed 2023-11-14 | |
| 2023-06-30 | -$291.30M 10-Q · filed 2023-08-14 | |
| 2023-03-31 | -$279.15M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | -$266.95M 10-K · filed 2024-04-01 | |
| 2022-09-30 | -$259.37M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | -$246.85M 10-Q · filed 2022-08-22 | |
| 2022-03-31 | -$237.48M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | -$219.49M 10-K · filed 2023-03-24 | |
| 2021-09-30 | -$205.18M 10-Q · filed 2021-11-17 | |
| 2021-06-30 | -$192.99M 10-Q · filed 2021-08-13 | |
| 2021-03-31 | -$178.91M 10-Q · filed 2021-05-17 | |
| 2020-12-31 | -$166.90M 10-K · filed 2022-03-11 | |
| 2020-09-30 | -$158.13M 10-Q · filed 2020-11-16 | |
| 2020-06-30 | -$150.26M 10-Q · filed 2020-08-13 | |
| 2020-03-31 | -$141.03M 10-Q · filed 2020-05-15 | |
| 2019-12-31 | -$133.09M 10-K · filed 2021-03-31 | -$133.09M 10-K · filed 2020-04-03 |
| 2019-09-30 | -$127.13M 10-Q · filed 2019-11-14 | |
| 2019-06-30 | -$119.58M 10-Q · filed 2019-08-14 | |
| 2019-03-31 | -$102.85M 10-Q · filed 2019-05-21 | |
| 2018-12-31 | -$94.55M 10-K · filed 2020-04-03 | |
| 2018-09-30 | -$81.90M 10-Q · filed 2018-11-19 | |
| 2018-06-30 | -$75.76M 10-Q · filed 2018-08-13 | |
| 2018-03-31 | -$68.10M 10-Q · filed 2018-05-15 | |
| 2017-12-31 | -$62.40M 10-K · filed 2019-04-10 | |
| 2017-09-30 | -$42.20M 10-Q · filed 2017-11-20 | |
| 2017-06-30 | -$46.96M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | -$45.15M 10-Q/A · filed 2017-06-23 | |
| 2016-12-31 | -$40.44M 10-K · filed 2018-04-09 | |
| 2016-09-30 | -$36.76M 10-Q · filed 2016-11-14 | |
| 2016-06-30 | -$33.34M 10-Q · filed 2016-08-15 | |
| 2016-03-31 | -$29.69M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | -$25.70M 10-K · filed 2017-02-15 | |
| 2015-09-30 | -$21.57M 10-Q · filed 2015-11-13 | |
| 2015-06-30 | -$18.61M 10-Q · filed 2015-08-13 | |
| 2015-03-31 | -$13.35M 10-Q · filed 2015-06-26 | |
| 2014-12-31 | -$9.41M 10-K · filed 2016-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |